XAIR

Beyond Air, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.93
52-Week Range: $2.38 – $55.60
Market Cap: $2.78M
P/E (TTM): —
EPS (TTM): -60.53
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.05
PEG Ratio: —
Return on Equity: -519.51%
Return on Assets: -57.45%
Gross Margin: 4.18%
Operating Margin: -373.98%
Profit Margin: 0.00%
Current Ratio: 3.31
Debt/Equity: 8.31
Total Debt: $23.60M
Free Cash Flow: $-14.07M
Revenue Growth: 0.50%
Earnings Growth: —
Enterprise Value: $17.33M

XAIR Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$0.00	$1.16M	$3.71M	$7.68M
Cost of Revenue	$555.00K	$2.47M	$5.37M	$7.43M
Gross Profit	-$555.00K	-$1.31M	-$1.66M	$252.00K
Research & Development	$16.81M	$24.36M	$16.86M	$10.24M
Selling, General & Admin	$34.69M	$37.34M	$26.02M	$19.05M
Operating Expenses	$51.50M	$61.70M	$42.87M	$29.30M
Operating Income	-$52.06M	-$63.01M	-$44.54M	-$29.04M
EBITDA	-$58.20M	-$59.03M	-$41.89M	-$27.17M
Pretax Income	-$59.40M	-$64.30M	-$48.48M	-$34.33M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$55.82M	-$60.24M	-$46.63M	-$33.25M
Diluted EPS	-744.00	-728.00	-276.00	-80.20
Diluted Shares	74934	82900	169266	415045

XAIR Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$29.16M	$11.38M	$4.67M	$6.74M
Receivables	$651.00K	$548.00K	$860.00K	$1.19M
Inventory	$1.13M	$2.13M	$2.42M	$1.41M
Current Assets	$59.41M	$43.94M	$16.02M	$24.77M
Total Assets	$68.75M	$56.96M	$30.06M	$35.38M
Current Liabilities	$19.78M	$11.57M	$5.00M	$6.51M
Long-Term Debt	$120.00K	$14.72M	$9.20M	$21.64M
Total Debt	$3.59M	$17.84M	$11.69M	$23.38M
Total Liabilities	$26.72M	$29.77M	$15.72M	$29.18M
Retained Earnings	-$179.46M	-$239.70M	-$286.32M	-$319.57M
Shareholders' Equity	$37.91M	$25.05M	$13.58M	$6.13M
Working Capital	$39.63M	$32.37M	$11.02M	$18.26M
Net Debt	—	$4.14M	$5.14M	$15.30M

XAIR Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$33.01M	-$56.01M	-$38.22M	-$18.14M
Capital Expenditure	-$3.88M	-$5.75M	-$5.88M	-$1.02M
Free Cash Flow	-$36.89M	-$61.76M	-$44.10M	-$19.17M
Depreciation & Amortisation	$1.17M	$2.35M	$3.57M	$3.65M
Stock-Based Compensation	$19.56M	$21.34M	$9.15M	$5.28M
Investing Cash Flow	-$20.59M	-$12.23M	$14.90M	-$3.67M
Financing Cash Flow	$2.70M	$43.17M	$16.65M	$29.09M
Net Change in Cash	-$50.90M	-$25.08M	-$6.67M	$7.27M

XAIR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.15M	$1.76M	$1.82M	$2.19M	$1.91M	$1.77M
Cost of Revenue	$1.18M	$1.60M	$2.12M	$1.89M	$1.81M	$1.54M
Gross Profit	-$32.00K	$156.00K	-$298.00K	$300.00K	$94.00K	$225.00K
Research & Development	$3.26M	$3.09M	$2.45M	$2.43M	$2.28M	$1.96M
Selling, General & Admin	$3.88M	$4.69M	$4.91M	$4.47M	$4.99M	$4.88M
Operating Expenses	$7.14M	$7.77M	$7.36M	$6.90M	$7.26M	$6.84M
Operating Income	-$7.17M	-$7.62M	-$7.66M	-$6.60M	-$7.17M	-$6.61M
EBITDA	-$6.54M	-$6.60M	-$6.70M	-$5.65M	-$8.21M	-$5.74M
Pretax Income	-$8.06M	-$8.08M	-$8.26M	-$7.63M	-$10.37M	-$8.15M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$8.03M	-$7.69M	-$7.94M	-$7.34M	-$10.28M	-$7.93M
Diluted EPS	-36.00	-613.40	-25.00	-17.00	-15.40	-220.00
Diluted Shares	224948	12537	317828	430843	664400	36066

XAIR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$4.67M	$4.98M	$9.70M	$6.64M	$6.74M	$5.51M
Receivables	$860.00K	$1.02M	$970.00K	$1.26M	$1.19M	$1.23M
Inventory	$2.42M	$2.43M	$2.23M	$1.76M	$1.41M	$1.29M
Current Assets	$16.02M	$14.99M	$18.59M	$25.56M	$24.77M	$22.85M
Total Assets	$30.06M	$28.11M	$30.96M	$36.77M	$35.38M	$32.89M
Current Liabilities	$5.00M	$4.63M	$4.38M	$4.99M	$6.51M	$6.91M
Long-Term Debt	$9.20M	$11.64M	$12.17M	$21.97M	$21.64M	$22.17M
Total Debt	$11.69M	$13.71M	$13.88M	$23.59M	$23.38M	$23.60M
Total Liabilities	$15.72M	$17.71M	$17.87M	$28.49M	$29.18M	$30.05M
Retained Earnings	-$286.32M	-$294.01M	-$301.95M	-$309.29M	-$319.57M	-$327.51M
Shareholders' Equity	$13.58M	$9.93M	$12.73M	$8.11M	$6.13M	$2.00M
Working Capital	$11.02M	$10.36M	$14.20M	$20.57M	$18.26M	$15.94M
Net Debt	$5.14M	$6.90M	$2.47M	$15.33M	$15.30M	$16.89M

XAIR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$6.96M	-$4.53M	-$4.45M	-$4.22M	-$4.95M	-$4.95M
Capital Expenditure	-$1.50M	-$198.00K	-$246.00K	-$34.00K	-$547.00K	-$208.00K
Free Cash Flow	-$8.46M	-$4.72M	-$4.70M	-$4.25M	-$5.49M	-$5.15M
Depreciation & Amortisation	$939.00K	$926.00K	$916.00K	$892.00K	$915.00K	$920.00K
Stock-Based Compensation	$158.00K	$1.58M	$1.77M	$1.50M	$427.00K	$1.04M
Investing Cash Flow	$2.58M	$576.00K	$240.00K	-$4.04M	-$447.00K	$461.00K
Financing Cash Flow	$4.50M	$4.07M	$8.92M	$11.21M	$4.90M	$3.06M
Net Change in Cash	$124.00K	$116.00K	$4.71M	$2.94M	-$492.00K	-$1.43M

Market Snapshot

About

Beyond Air, Inc. is a clinical-stage medical device and pharmaceutical company developing innovative nitric oxide (NO) delivery systems for respiratory and other diseases. The company's lead product, LungFit, delivers precisely metered doses of nitric oxide for the treatment of conditions including persistent pulmonary hypertension of the newborn and bronchiolitis. Beyond Air is focused on leveraging the therapeutic benefits of nitric oxide to address unmet medical needs.